Clinical Trial Search

Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338

Primary: Treatment-specific Baseline Estimated Glomerular Filtration Rate Based on Creatinine (eGFRcr) — 32.7; 34.9 mL/min/1.73m^2

Primary: Change in Urinary Albumin:Creatinine Ratio (ACR) — -52.55555556; 46.44444444 ratio

Primary: MCP-1:Creatinine Ratio in Urine — 27.9; 24.3 ng/mmol

Primary: Change in Urine Albumin Excretion — -21; -5 percent difference

Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min

Primary: Change in Proteinuria — -34; -133 mg/g creatinine — p=0.04

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: Change in eGFR From Baseline at Week 48 — -2.83; -2.37; -4.07; -3.20 mL/min/1.73 m^2 — p=0.755

Primary: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in 10-hour Urine After 20 Weeks of Trial Treatment — -0.069; -0.029; -0.217; 0.034…

Primary: Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR) — 3.2; 17.7; 5.4 Geometric Mean of Percent Change — p=0.485

Primary: Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24 — 1.12; 0.87; 0.85; 0.91 milligram/gram (mg/g)

Primary: Glycemic Control — 7.4; 7.35 percentage of HbA1c — p=0.37

Primary: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death — 504…

Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045

Primary: Change From Baseline in eGFR at 6 Months (Patient-specific) — -2.35; -4.24 mL/min/1.73m^2

Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline

Primary: GFR (Glomerular Filtration Rate) Change After Treatment — 22; 1; 8; 0 ml/min/1.73m^2

Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01

Primary: Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF]) — -2.92; -10.76; -3.40 % Change…

Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Change From Baseline in Urinary Albumin Excretion — 50.5; -28.13; -4.5; 96.6 mg/g

Primary: Change in Estimated Glomerular Filtration Rate — -12.3; -13.1; -12.2; -13.1 mL/min/1.73m2 — p=0.25

Primary: Change From Baseline in eGFR at 3 Months (Patient-specific) — -1.71; -4.12 ml/min/1.73m^2

Primary: the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI — 22.04 1/ms

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999

Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants

Primary: Part B:Change From Baseline in Proteinuria — 1.5; -0.4; 0.1; 0.7 grams per 12 hour (g/12 hour) — p=0.0449